Crystalline form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol

US11065255B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Michael Lange · Darmstadt, DE
• Clemens Kuehn · Darmstadt, DE
• Thomas Fuchss · Bensheim, DE
• David Maillard · Coventry, GB
• Marcel Breuning · Frankfurt am Main, DE
• Marco Poma · Grosseto, IT
• Edoardo Burini · Guidonia, IT

Key dates

• Filing date: Mar 28, 2018
• Grant date: Jul 20, 2021
• Expiry date: Jun 18, 2038

Classification

• Technology area (CPC —): General

Abstract

A crystalline form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)-phenyl]-(6-methoxy-pyridazin-3-yl)-methanol can be prepared as a pharmaceutical composition.